• Tuesday, March 24, 2020 @ 12:00 am

Santersus AG has now solidified a deal with SAKK the Swiss Cancer Institute to further the development of its technology in the field of oncology.
“Our initial indication is of course Sepsis however we have realized the potential for this technology to disrupt multiple therapeutic and diagnostic areas including oncology. We wanted to establish this relationship to allow clinicians in this institution to further their understanding and how we can implement this into further treatment and diagnostic modalities”.

You may also be interested in